Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675778 · ClinicalTrials.gov registry record · Phase 2
Association Between Body Size and Response to Hydromorphone in ED
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT01675778: Completed Phase 2 study, sponsored by Albert Einstein College of Medicine.
NCT01675778 is a Phase 2 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 174 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01675778, a Phase 2 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
Pain is the most common complaint for patients presenting to the emergency department (ED). Inadequate pain relief is also a common problem in ED. Patients' pain perceptions and responses to intravenous opioids vary widely and are influenced by multiple factors. The objective of the current study is to examine the association between total body weight, BMI (body mass index) and clinical response to a fixed dose of intravenous hydromorphone.
Primary Outcome
Participants were asked to rate their pain levels from 0 (=no pain) to 10 (= worst pain). The change in pain intensity was determined by subtracting the intensity reported before treatment from the intensity reported 30 minutes after treatment. Pearson correlation was used to assess the correlation between change in pain intensity and total body weight (TBW). The reported value represents the correlation coefficient.
Interventions
- DRUG Hydromorphone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT01675778 record still lists
NCT01675778 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 1 intervention - of which Hydromorphone is the first listed.
NCT01675778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01675778 about?
NCT01675778 is a clinical study titled "Association Between Body Size and Response to Hydromorphone in ED". Pain is the most common complaint for patients presenting to the emergency department (ED). Inadequate pain relief is also a common problem in ED. Patients' pain perceptions and responses to intravenous opioids vary widely and are influenced by multiple factors. The objective of the current study is...
What is the current status of trial NCT01675778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2011-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01675778?
The interventions under investigation include: Hydromorphone (DRUG).
Who is sponsoring clinical trial NCT01675778?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01675778's enrollment target sits among peer trials
174 396th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia